Declaration of Clinical Research Rights and Responsibilities
for People With Parkinson’s

Return to Webpage

Clinical research is essential to the development of new therapies and treatments for Parkinson’s disease. Yet, due to a number of factors, including a lack of awareness and understanding of the research process, only one percent of people with Parkinson’s participate. This is far below the number needed, delaying many promising trials. 

Those who do participate in clinical studies assume risk to help advance science through research, but are not always fully aware of their rights and responsibilities. To remedy this, the Parkinson's Pipeline Project and additional people with Parkinson's developed this Declaration of Clinical Research Rights and Responsibilities.  This document was created with advisement from the Parkinson's Disease Foundation through their People with Parkinson's Clinical Research Advocacy Initiative.  The intent of this document is to:

  • Educate the Parkinson’s community about the clinical research process.
  • Empower People With Parkinson’s to make informed decisions about their clinical trial participation.
  • Increase participation in clinical trials to speed the evaluation and approval of new treatments.
  • Provide the research team with a roadmap for developing and conducting patient-centered clinical research.
  • Ultimately, inspire a culture shift where the participant is viewed as a partner, not a passive subject in the clinical research process.

In order to achieve these goals, this document outlines rights and responsibilities for clinical trial participants with Parkinson’s disease, including:

  1. The right to receive comprehensive information about a clinical trial prior to enrollment and throughout the trial.
  2. The right to timely reimbursement for all expenses associated with clinical trial. participation. 
  3. The right to withdraw from a clinical trial at any time without penalty.
  4. The right to be informed when a sponsor is considering halting or terminating a trial.
  5. The right to post-study information and options for care.
  6. The right to be assured that participation in clinical research will contribute to the scientific evidence necessary to evaluate new and more effective treatments.

It is assumed that all clinical study information will be communicated verbally and in writing in the primary language of the participant and at an appropriate reading level.  Those rights marked with an asterisk (*) are based on existing federal regulations governing the informed consent process.

  1. Clinical trial participants with Parkinson’s disease have the right to receive comprehensive information about a clinical trial prior to enrollment. They should be informed about:
  • Potential risks and benefits.*
  • Study design, including: purposes and expected outcomes, duration, required medical tests/procedures, and if applicable, the percentage of participants who will receive a placebo.*
  • Conditions under which a trial or an individual’s trial participation may be terminated without their consent. *
  • Other procedures, drugs, devices or treatments that may benefit the participant. *
  • How enrollment in a clinical trial could make participants ineligible for future trials, especially those testing neuroprotective treatments requiring  participants who have not previously taken other Parkinson’s medications.
  • The opportunity to take home, review, and discuss all study information with medical professionals before deciding to enroll in the trial
  • The difference between the roles of doctors as personal physicians and as clinical trial investigators. A personal physician’s responsibility is to safeguard the best interests of the patient. A clinical trial investigator’s responsibility is to do what is best for the research study.
  • Availability and procedures for obtaining compensation and/or medical treatment necessary due to injury resulting from the clinical trial, and whom to contact.*
  • Who has access to the data collected and how participant privacy will be protected. * 
  • Trial staff should evaluate participants’ full understanding of the informed consent document before they sign it.
  • The option to have a caregiver, family member, or other trusted person present during discussion and review of clinical trial information.
  • Contact information for trial staff responsible for answering questions about the trial.*
  • How to access published information about the investigational treatment.
  • Financial associations between the study sponsor and clinical trial staff

The participant has the responsibility to:

bullet Read all materials provided about the trial and treatment being considered and ask questions when information is unclear.
  1. Clinical trial participants with Parkinson’s have a right to timely reimbursement for all expenses associated with trial participation:
  • Access, where available, to a trained patient representative who can assist with communication between the participant and the research team.
  • The opportunity, where available, to create an Advance Directive for medical research and appoint a legally authorized representative to make medical and research decisions if the individual becomes unable to do so.
  • The option to consult, at any time, with a personal physician not involved in the study.
  • The procedure for reporting and resolving problems with clinical trial staff. Where these issues cannot be resolved on site, a trained patient representative, where available, may be asked to mediate. If mediation fails, participants may request referral to a different trial researcher or site, if available.
  • New findings, including adverse events and side effects, as they develop. 
  • What they can and cannot tell others about the study, and why

The participant has the responsibility to:

bullet Become familiar with the trial site staff and their respective responsibilities.
bullet Provide a complete medical history prior to the trial, and report all new illnesses, injuries, and elective medical procedures that occur during the trial.
bullet Be available for each required  test, procedure and clinical evaluation ..
bullet Follow  all trial instructions
bullet Submit all related personal expense receipts in a timely manner for reimbursement.
bullet Contact the designated trial staff member prior to each scheduled appointment regarding any pre-paid expenses.
  1. Clinical trial participants with Parkinson’s disease have the right to withdraw from a clinical trial at any time without penalty, and are entitled to receive:
  • Non-medical expenses, such as lodging, transportation, and meals, monetary losses due to absence from work for the participant and accompanying caregiver will be arranged and paid for in advance, when possible.
  • All out-of-pocket expenses will be reimbursed in a timely manner.

The participant has the responsibility to:

bullet Submit all related personal expense receipts in a timely manner for reimursement.
bullet Contact the designated trial staff member prior to each scheduled appointment regarding any pre-paid expenses..
  1. Clinical trial participants with Parkinson’s disease have the right to be informed when a sponsor is considering halting or terminating a trial.
  • A designated trial staff member should advise participants of a trial halt, at the same time it is publicly announced, and explain the reason(s) for the halt and how to proceed with remaining trial medications or devices.
  1. Clinical trial participants with Parkinson’s disease have the right to post-study information and options for care including:
  • Trial results.
  • Information about the conditions under which they may receive post-trial access to the experimental treatment.
  • Notification as to whether they received a placebo or the experimental treatment and at what dosage.
  • The option for participants in the experimental/treatment group to continue the treatment. Likewise, those who received placebo or low dose treatments, or sham surgery should have the option of receiving the experimental treatment at the full dose, upon conclusion of their trial.
  • Results of all tests and procedures and copies of scans, x-rays, MRI’s, etc. if requested by the participant.
  • Updates about all adverse events following trial conclusion.

The participant has the responsibility to:

bullet Submit in writing any change of address and/or phone number..

  1. Clinical trial participants with Parkinson’s have the right to be assured that their participation in clinical research will contribute to the scientific evidence necessary to evaluate new and more effective treatments. To lay the groundwork for this:
  • Patient reported outcomes should be collected and considered.
  • Study sponsors will be required to list all clinical trials with appropriate registries.
  • Study sponsors will be required to make publicly available, in a timely and complete manner, all positive and negative trial results.

The participant has the responsibility to:

bullet Provide accurate and honest feedback to trial staff about their response to the treatment..
bullet Use the trial experience, to help encourage greater clinical trial participation in the Parkinson’s community.
bullet Make every effort to continue in the trial until its conclusion, recognizing that participant retention is important in obtaining useful data.

Copyright © 2004-2006 Parkinson Pipeline Project.

www.pdpipeline.org

All rights reserved. Revised: 02/22/11.